Hormone replacement therapy and the risk of endometrial cancer: A systematic review

Maturitas

Volumn 91, Issue , 2016, Pages 25-35

  Sjögren, Lea L ^a   Mørch, Lina S ^b   Løkkegaard, Ellen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Endometrial cancer; Hormone therapy; Menopause; Micronized progesterone; Risk assessment; Systematic review

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO; PROGESTERONE; TIBOLONE;

BIBLIOGRAPHIC DATABASE; CANCER RISK; COHORT ANALYSIS; COMPARATIVE STUDY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MEDICAL HISTORY; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROGESTIN THERAPY; REVIEW; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; ENDOMETRIAL NEOPLASMS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE;

ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; PROGESTINS; RISK FACTORS;

EID: 84975282586     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2016.05.013     Document Type: Review

References (43)

1. S. Palacios, V.W. Henderson, N. Siseles, D. Tan, and P. Villaseca Age of menopause and impact of climacteric symptoms by geographical region Climacteric 13 5 2010 419 428
2. S. Furness, H. Roberts, J. Marjoribanks, and A. Lethaby Hormone therapy in postmenopausal women and risk of endometrial hyperplasia Cochrane Database Syst. Rev. 8 2012 CD000402
3. M.C. Politi, M.D. Schleinitz, and N.F. Col Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis J. Gen. Intern. Med. 23 9 2008 1507 1513
4. NAMS The 2012 hormone therapy position statement of: the North American menopause society Menopause 19 3 2012 257 271
5. F.Z. Stanczyk, J.P. Hapgood, S. Winer, and D.R. Mishell Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions and clinical effects Endocr. Rev. 34 2 2013 171 208
6. S. Yang, K.W. Thiel, and K.K. Leslie Progesterone the ultimate endometrial tumor suppressor Trends Endocrinol. Metab. 22 4 2011 145 152
7. A. Lukanova, E. Lundin, A. Zeleniuch-Jacquotte, P. Muti, A. Mure, S. Rinaldi, and et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women Eur. J. Endocrinol. 150 2 2004 161 171
8. S.D. Reed, K.M. Newton, W.L. Clinton, M. Epplein, R. Garcia, K. Allison, and et al. Incidence of endometrial hyperplasia Am. J. Obstet. Gynecol. 200 6 2009 e1 e6 (678)
9. RCOG/BSGE Management of Endometrial Hyperplasia 2016 Royal College of Obstetricians and Gynaecologists (RCOG) and the British Society of Gynaecological Endoscopy (BSGE)
10. NORDCAN, 2015.
11. NICE Menopause: Diagnosis and Management 2015 NICE Guidelines (NG23)
12. G. Formoso, E. Perrone, S. Maltoni, S. Balduzzi, R. D'Amico, C. Bassi, and et al. Short and long term effects of tibolone in postmenopausal women Cochrane Database Syst. Rev. 2 2012 CD008536
13. J. Marjoribanks, C. Farquhar, H. Roberts, and A. Lethaby Long term hormone therapy for perimenopausal and postmenopausal women Cochrane Database Syst. Rev. 7 2012 CD004143
14. A. Fournier, L. Dossus, S. Mesrine, A. Vilier, M.C. Boutron-Ruault, F. Clavel-Chapelon, and et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008 Am. J. Epidemiol. 180 5 2014 508 517
15. L.S. Mørch, S.K. Kjaer, N. Keiding, E. Løkkegaard, and ∅. Lidegaard The influence of hormone therapies on type I and II endometrial cancer: a nationwide cohort study Int. J. Cancer 138 6 2016 1506 1515
16. L.E. Nachtigall, R.H. Nachtigall, R.D. Nachtigall, and E.M. Beckman Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems Obstet. Gynecol. 54 1 1979 74 79
17. PEPI Effects of hormone replacement therapy on endometrial histology in postmenopausal women. the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI trial JAMA 275 5 1996 370 375
18. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group JAMA 280 7 1998 605 613
19. I. Byrjalsen, N.H. Bjarnason, and C. Christiansen Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy Am. J. Obstet. Gynecol. 180 3 Pt 1 1999 539 549
20. J.C. Gallagher, D.J. Baylink, R. Freeman, and M. McClung Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies J. Clin. Endocrinol. Metab. 86 10 2001 4717 4726
21. A. Ferenczy, M.M. Gelfand, P.H. van de Weijer, and J.E. Rioux Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone Climacteric 5 1 2002 26 35
22. Women's Health Initiative I Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial JAMA 288 3 2002 321 333
23. R.D. Langer, B.M. Landgren, J. Rymer, and F.A. Helmond Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study Am. J. Obstet. Gynecol. 195 5 2006 1320 1327
24. S.R. Cummings, B. Ettinger, P.D. Delmas, P. Kenemans, V. Stathopoulos, P. Verweij, and et al. The effects of tibolone in older postmenopausal women N. Engl. J. Med. 359 7 2008 697 708
25. P. Kenemans, N.J. Bundred, J.M. Foidart, E. Kubista, B. von Schoultz, P. Sismondi, and et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial Lancet Oncol. 10 2 2009 135 146
26. E. Pukkala, A. Tulenheimo-Silfvast, and A. Leminen Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997 Cancer Causes Control 12 2 2001 111 115
27. C.S. de Vries, S.E. Bromley, H. Thomas, and R.D. Farmer Tibolone and endometrial cancer: a cohort and nested case-control study in the UK Drug Saf. 28 3 2005 241 249
28. J.V. Lacey Jr., L.A. Brinton, J.H. Lubin, M.E. Sherman, A. Schatzkin, and C. Schairer Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women Cancer Epidemiol. Biomarkers Prev. 14 7 2005 1724 1731
29. B. Trabert, N. Wentzensen, H.P. Yang, M.E. Sherman, A.R. Hollenbeck, Y. Park, and et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int. J. Cancer 132 2 2013 417 426
30. I. Persson, E. Weiderpass, L. Bergkvist, R. Bergstrom, and C. Schairer Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement Cancer Causes Control 10 4 1999 253 260
31. A. Paganini-Hill, R.K. Ross, and B.E. Henderson Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study Br. J. Cancer 59 3 1989 445 447
32. L. Sourander, T. Rajala, I. Räihä, J. Mäkinen, R. Erkkola, and H. Helenius Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT) Lancet 352 9145 1998 1965 1969
33. K. Bakken, E. Alsaker, A.E. Eggen, and E. Lund Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study Int. J. Cancer 112 1 2004 130 134
34. V. Beral, D. Bull, G. Reeves, and M.W.S. Collaborators Endometrial cancer and hormone-replacement therapy in the million women study Lancet 365 9470 2005 1543 1551
35. N.E. Allen, K.K. Tsilidis, T.J. Key, L. Dossus, R. Kaaks, E. Lund, and et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition Am. J. Epidemiol. 172 12 2010 1394 1403
36. A.J. Canchola, E.T. Chang, L. Bernstein, J.A. Largent, P. Reynolds, D. Deapen, and et al. Body size and the risk of endometrial cancer by hormone therapy use in postmenopausal women in the California teachers study cohort Cancer Causes Control 21 9 2010 1407 1416
37. S. Karageorgi, S.E. Hankinson, P. Kraft, and I. De Vivo Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the nurses' health study cohort 1976-2004 Int. J. Cancer 126 1 2010 208 216
38. N. Cherry, R. McNamee, A. Heagerty, H. Kitchener, and P. Hannaford Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial BJOG 121 6 2014 700 705 Discussion 5
39. H.K. Ziel, and W.D. Finkle Increased risk of endometrial carcinoma among users of conjugated estrogens N. Engl. J. Med. 293 23 1975 1167 1170
40. D.C. Smith, R. Prentice, D.J. Thompson, and W.L. Herrmann Association of exogenous estrogen and endometrial carcinoma N. Engl. J. Med. 293 23 1975 1164 1167
41. D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster, and D. Petitti Hormone replacement therapy and endometrial cancer risk: a meta-analysis Obstet. Gynecol. 85 2 1995 304 313
42. T.J. de Villiers, M.L. Gass, C.J. Haines, J.E. Hall, R.A. Lobo, D.D. Pierroz, and et al. Global consensus statement on menopausal hormone therapy Climacteric 16 2 2013 203 204
43. V.W. Setiawan, H.P. Yang, M.C. Pike, S.E. McCann, H. Yu, Y.B. Xiang, and et al. Type I. and II endometrial cancers: have they different risk factors? J. Clin. Oncol. 31 20 2013 2607 2618